BACE inhibitors, which decrease BACE1 (β-secretase) cleavage of the amyloid precursor protein (APP) and subsequently reduce neurotoxic amyloid-β (Aβ) levels, have been in clinical trials for the treatment of Alzheimer’s disease. Here, APP is linked to Alzheimer disease.